AMT-116

DRUG4 trials

Sponsors

Multitude Therapeutics Inc.

Conditions

Advanced Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorAdvanced Solid TumorsNSCLC (Advanced Non-small Cell Lung Cancer)

Phase 1

AMT-116 in Patients With Advanced Solid Tumors

RecruitingNCT05725291

Multitude Therapeutics Inc.Advanced Solid Tumor

Start: 2023-07-25End: 2026-12-30Target: 80Updated: 2025-08-17

AMT-116 in Patients with Solid Tumors

RecruitingNCT06782334

Multitude Therapeutics Inc.Advanced Solid Tumors

Start: 2024-05-07End: 2026-12-30Target: 144Updated: 2025-01-17

AMT-116 in Combination With AK112 in Patients With Lung Cancer

RecruitingNCT07590531

Multitude Therapeutics Inc.Advanced Non-small Cell Lung Cancer (NSCLC)

Start: 2026-06-29End: 2027-12-31Target: 118Updated: 2026-08-10

Phase 2

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Not yet recruitingNCT07718737

Multitude Therapeutics Inc.NSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2026-08-28End: 2028-12-30Target: 512Updated: 2026-08-10

Related Papers

Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-01